• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » SpineGuard IPO drums up $11M

SpineGuard IPO drums up $11M

April 29, 2013 By Brad Perriello

SpineGuard

SpineGuard  (EPA:ALSGD) said its initial public offering on Europe’s Alternext exchange raised some €8.1 million, or roughly $10.5 million.

The Paris-based medical device company makes the PediGuard device, designed to help guide the placement of pedicle screws during spinal fusion surgeries.

The IPO went off at €7.29 per share, or about $9.50 apiece, giving SpineGuard an initial market capitalization of about €31.4 million ($40.8 million), according to a press release.

"We are delighted to announce today the success of SpineGuard’s IPO on Alternext despite particularly difficult financial market conditions," co-founder & CEO Pierre Jérôme said in prepared remarks. "This IPO represents a major step for the company in establishing the PediGuard device as a standard of care in pedicle screw placement at the very moment we have reached the milestone of 25,000 surgeries. We warmly thank all our new shareholders joining us today, our historical shareholders who have supported us for the past four years, our employees in the USA and France and our partners worldwide without whom we would not have reached this milestone. With the raised funds, we will be able to accelerate our commercial expansion and the development of our platform technology."

ALSGD shares traded as high as €7.65 apiece today, up 4.9%.

Filed Under: Initial Public Offering (IPO), News Well, Spine, Wall Street Beat Tagged With: SpineGuard

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy